CN118027160A - Preparation method of recombinant Aeromonas hydrophila Hcp protein - Google Patents
Preparation method of recombinant Aeromonas hydrophila Hcp protein Download PDFInfo
- Publication number
- CN118027160A CN118027160A CN202410113384.1A CN202410113384A CN118027160A CN 118027160 A CN118027160 A CN 118027160A CN 202410113384 A CN202410113384 A CN 202410113384A CN 118027160 A CN118027160 A CN 118027160A
- Authority
- CN
- China
- Prior art keywords
- hcp
- protein
- recombinant
- aeromonas hydrophila
- expression
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 96
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 93
- 241000607528 Aeromonas hydrophila Species 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims abstract description 7
- 230000014509 gene expression Effects 0.000 claims abstract description 23
- 230000006698 induction Effects 0.000 claims abstract description 16
- 101150069782 hcp gene Proteins 0.000 claims abstract description 13
- 238000000746 purification Methods 0.000 claims abstract description 9
- 238000010276 construction Methods 0.000 claims abstract description 5
- 230000009465 prokaryotic expression Effects 0.000 claims abstract description 5
- 239000013613 expression plasmid Substances 0.000 claims abstract description 4
- 238000005457 optimization Methods 0.000 claims abstract description 3
- 230000002194 synthesizing effect Effects 0.000 claims abstract description 3
- 238000000034 method Methods 0.000 claims description 19
- 239000013612 plasmid Substances 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 13
- 238000011084 recovery Methods 0.000 claims description 12
- 239000006228 supernatant Substances 0.000 claims description 12
- 239000000047 product Substances 0.000 claims description 11
- 230000008569 process Effects 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 9
- 230000001580 bacterial effect Effects 0.000 claims description 8
- 239000007788 liquid Substances 0.000 claims description 8
- 239000002244 precipitate Substances 0.000 claims description 8
- 239000013598 vector Substances 0.000 claims description 8
- 238000001976 enzyme digestion Methods 0.000 claims description 7
- 238000009835 boiling Methods 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 239000003292 glue Substances 0.000 claims description 6
- 239000012160 loading buffer Substances 0.000 claims description 6
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 claims description 6
- 230000001939 inductive effect Effects 0.000 claims description 5
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 claims description 5
- 238000012408 PCR amplification Methods 0.000 claims description 4
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 claims description 4
- 238000005520 cutting process Methods 0.000 claims description 4
- 238000001962 electrophoresis Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 108091008146 restriction endonucleases Proteins 0.000 claims description 4
- 102000003960 Ligases Human genes 0.000 claims description 3
- 108090000364 Ligases Proteins 0.000 claims description 3
- 229960000723 ampicillin Drugs 0.000 claims description 3
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 3
- 230000003698 anagen phase Effects 0.000 claims description 3
- 239000000872 buffer Substances 0.000 claims description 3
- 230000009089 cytolysis Effects 0.000 claims description 3
- 238000000605 extraction Methods 0.000 claims description 3
- 210000003000 inclusion body Anatomy 0.000 claims description 3
- 238000012163 sequencing technique Methods 0.000 claims description 3
- 238000012258 culturing Methods 0.000 claims description 2
- 238000001556 precipitation Methods 0.000 claims description 2
- 150000001413 amino acids Chemical class 0.000 abstract description 14
- 238000004458 analytical method Methods 0.000 abstract description 8
- 101000937129 Drosophila melanogaster Cadherin-related tumor suppressor Proteins 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 68
- 230000026731 phosphorylation Effects 0.000 description 7
- 238000006366 phosphorylation reaction Methods 0.000 description 7
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 4
- 239000004473 Threonine Substances 0.000 description 4
- 238000009360 aquaculture Methods 0.000 description 4
- 244000144974 aquaculture Species 0.000 description 4
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 230000003321 amplification Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000001502 gel electrophoresis Methods 0.000 description 3
- 238000003199 nucleic acid amplification method Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
- 241000251468 Actinopterygii Species 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- 206010017472 Fumbling Diseases 0.000 description 2
- 108010046179 Type VI Secretion Systems Proteins 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 239000003228 hemolysin Substances 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- 241000607534 Aeromonas Species 0.000 description 1
- 241000143060 Americamysis bahia Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102100023344 Centromere protein F Human genes 0.000 description 1
- 102000012410 DNA Ligases Human genes 0.000 description 1
- 108010061982 DNA Ligases Proteins 0.000 description 1
- 230000004544 DNA amplification Effects 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010006464 Hemolysin Proteins Proteins 0.000 description 1
- 102000004310 Ion Channels Human genes 0.000 description 1
- 108090000862 Ion Channels Proteins 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010006519 Molecular Chaperones Proteins 0.000 description 1
- 102000018819 Protein Translocation Systems Human genes 0.000 description 1
- 206010040047 Sepsis Diseases 0.000 description 1
- 101710172711 Structural protein Proteins 0.000 description 1
- 108010046504 Type IV Secretion Systems Proteins 0.000 description 1
- 241000607493 Vibrionaceae Species 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 235000013882 gravy Nutrition 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003950 pathogenic mechanism Effects 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 238000001742 protein purification Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 101150038846 slc46a1 gene Proteins 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 239000000304 virulence factor Substances 0.000 description 1
- 230000007923 virulence factor Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/70—Vectors or expression systems specially adapted for E. coli
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
Abstract
The invention provides a preparation method of recombinant aeromonas hydrophila Hcp protein, which belongs to the technical field of biology, and comprises the following steps: step 1: designing and synthesizing a primer; step 2: amplifying the Hcp gene; step 3: construction of prokaryotic expression plasmid pET-32 a-Hcp; step 4: performing induction expression and expression condition optimization of recombinant Hcp protein; step 5: identification and purification of the expression form of the recombinant Hcp protein. The Hcp protein belongs to hydrophilic protein, the hydrophobicity of amino acid 117 is strongest, the value is 1.433, and the hydrophilicity of amino acid 55 is strongest, the value is-1.911. The protein fat coefficient was 73.66, the instability coefficient was 32.03, and the protein was stable. The Hcp protein was analyzed for hydrophilicity and hydrophobicity using ProtScale, with amino acid scores less than 0 indicating hydrophilicity and scores greater than 0 indicating hydrophobicity. Analysis shows that most amino acids of the Hcp protein are located in the hydrophilic region, are hydrophilic proteins, and are consistent with the physicochemical analysis result of the proteins.
Description
Technical Field
The invention relates to the technical field of biology, in particular to a preparation method of recombinant aeromonas hydrophila Hcp protein.
Background
Aeromonas hydrophila (Aeromonas hydrophila, AH) is gram-negative bacteria belonging to the genus Aeromonas of the family Vibrionaceae, is a conditional pathogenic bacteria commonly existing in various water bodies, soil and environments, is one of normal flora species in a culture water environment, can cause various diseases of fishes, animals and people, and can induce fish infection septicemia. Bringing great economic loss to the aquaculture industry at home and abroad. At present, the AH infection is mainly inhibited by antibiotics in the aquaculture industry, and the abuse of antibiotics not only can cause AH to generate drug resistance, but also can influence the ecological environment and the food safety quality, thereby causing food quality safety problems and ecological safety problems. Aquatic organisms in aquaculture are susceptible to attack by AH and disease. The individual shrimps are smaller, the treatment is not practical one by one, and the shrimp groups are difficult to treat in the water body. Therefore, it is important to control the continuous outbreak of this bacterium in the population and aquaculture.
The pathogenic mechanisms of AH are complex, and disease in the host is usually dependent on interactions between the secretory system and virulence factors. The type IV secretion system (Type VI secretion system, T6 SS) is one of the secretion systems of AH, consisting of 13 proteins, responsible for the transport of part of effector proteins outside the cell. The hemolysin co-regulated protein (Hcp) is one of the protein components of T6SS, and Hcp protein can form a tube-like hexamer to assist T6SS in secreting virulence related proteins. Hcp proteins play an important role in the T6SS system, both as structural proteins that help form the injection device secretion proteins and as effector proteins that can be secreted extracellularly to enhance virulence. The existing haemolysin cotodulatory protein is difficult to obtain, so that a preparation method of recombinant aeromonas hydrophila Hcp protein needs to be designed.
Disclosure of Invention
The invention aims to provide a preparation method of recombinant aeromonas hydrophila Hcp protein, which solves the technical problem that the existing aeromonas hydrophila Hcp protein is difficult to obtain.
In order to achieve the above purpose, the technical scheme adopted by the invention is as follows:
a method for preparing recombinant aeromonas hydrophila Hcp protein, said method comprising the steps of:
step 1: designing and synthesizing a primer;
step 2: amplifying the Hcp gene;
Step 3: construction of prokaryotic expression plasmid pET-32 a-Hcp;
Step 4: optimizing the induction expression and expression conditions of the recombinant Hcp protein;
step 5: identification and purification of the expression form of the recombinant Hcp protein.
Further, the specific process of the step 1 is as follows:
designing an Hcp gene specific primer according to the sequence of the Hcp gene, wherein restriction enzyme cutting sites are EcoR I and Xho I respectively;
Hcp-F:5'--3':CCGGAATTCATGCCAACTCCATGTTATAT;
Hcp-R:5'--3':CGGCTCGAGTTACGCCTCGATCGGAGCAC。
further, the specific process of the step 2 is as follows:
PCR amplification is carried out by taking DNA of AH-SC-3 as a template and Hcp-F/R as a primer pair, and the PCR product is subjected to gel recovery according to the operation instruction of a gel recovery kit.
Further, the specific process of the step 3 is as follows:
And (3) carrying out double enzyme digestion on a glue recovery product of the target gene Hcp and a pET-32a (+) vector, then carrying out glue recovery again, connecting the two fragments according to a T4 ligase specification, converting the connecting product into DH5 alpha competent cells according to a DH5 alpha competent cell using specification, extracting plasmids according to a plasmid extraction kit operating specification after single colony propagation in the next day, carrying out enzyme digestion identification and sequencing on the obtained plasmids, and naming the plasmids as pET-32a-Hcp.
Further, the specific process of step4 is as follows:
pET-32a-Hcp is transformed into BL21 competent cells according to the specification, the BL21 competent cells are coated on an ampicillin-resistant LA plate, the LA plate is cultured for 12 hours in a constant temperature incubator at 37 ℃, single colony is selected for culturing at 37 ℃ and at 150rpm, part of bacterial liquid is taken for PCR identification, positive clones which are identified correctly are subjected to enrichment culture, optimal induction conditions are determined by adding different doses of IPTG and changing induction time after the logarithmic growth phase is reached, supernatant is discarded after 8-000 rpm 3min of bacterial liquid is collected, 40 mu L of PBS is added for resuspension precipitation and mixing with 10 mu L of 5X Loading Buffer, and SDS-PAGE electrophoresis is carried out after 10min of boiling water bath.
Further, the specific process of step 5 is as follows:
performing ultrasonic lysis on the expressed bacterial liquid, separating supernatant and precipitate at 4 000rpm for 10min, dissolving the precipitate in Inclusion Body Elutio Buffer, mixing 40 mu L of supernatant and precipitate solution with 10 mu L of 5× Loading Buffer, performing SDS-PAGE electrophoresis after 10min in boiling water, determining expression form, inducing, and purifying protein according to the method in the purification kit.
Due to the adoption of the technical scheme, the invention has the following beneficial effects:
The Hcp protein belongs to hydrophilic protein, the hydrophobicity of amino acid No. 117 is strongest, the value is 1.433, and the hydrophilicity of amino acid No. 55 is strongest, the value is-1.911. The protein fat coefficient was 73.66, the instability coefficient was 32.03, and the protein was stable. The Hcp protein was analyzed for hydrophilicity and hydrophobicity using ProtScale, with amino acid scores less than 0 indicating hydrophilicity and scores greater than 0 indicating hydrophobicity. Analysis shows that most amino acids of the Hcp protein are located in hydrophilic areas, are hydrophilic proteins, and are consistent with the physicochemical analysis result of the proteins, and the proteins mainly comprise random curls, extension chains, alpha-helices and beta-corners. Hcp acts as an export carrier and chaperone for effector proteins and may be attached by covalent extension of these components or by non-covalent interactions. Therefore, the Hcp protein can also be used as a marker for normal production of T6SS function
Drawings
FIG. 1 is a diagram showing the results of double digestion of the recombinant plasmid pET-32a-Hcp of the invention;
FIG. 2 is an optimized view of the conditions for inducible expression of the pET-32a-Hcp recombinant protein of the invention;
FIG. 3 is a graph showing the results of expression and purification of the pET-32a-Hcp recombinant protein of the invention;
FIG. 4 is a graph of the hydrophilic-hydrophobic analysis of the Hcp protein of the invention;
FIG. 5 is a graph showing the prediction of the Hcp protein signal peptide of the invention;
FIG. 6 is a predicted view of the Hcp protein transmembrane domain of the invention;
FIG. 7 is a map of the phosphorylation site prediction of the Hcp protein of the invention;
FIG. 8 is a diagram of the Hcp protein conserved domain of the invention;
FIG. 9 is a predicted graph of the secondary structure of the Hcp protein of the invention;
FIG. 10 is a predicted map of the tertiary structure of the Hcp protein of the invention.
Detailed Description
In order to make the objects, technical solutions and advantages of the present invention more apparent, the present invention will be further described in detail below by referring to the accompanying drawings and by illustrating preferred embodiments. It should be noted, however, that many of the details set forth in the description are merely provided to provide a thorough understanding of one or more aspects of the invention, and that these aspects of the invention may be practiced without these specific details.
A method for preparing recombinant aeromonas hydrophila Hcp protein, said method comprising the steps of:
1 materials and methods
Step 1: strain and vector
The AH-SC-3 strain was isolated, identified and deposited by the China center for type culture Collection (M2023860); pET-32a (+) vector was purchased from Biotechnology (Shanghai) Inc., DH 5. Alpha. BL21 (DE 3) competent cells were purchased from Shanghai high-feather Biotechnology Inc.
Step 2: main reagent and instrument
Restriction enzymes EcoR I and Xho I, T4 DNA LIGASE were purchased from Bao Ri doctor materials technology (Beijing) Co., ltd; plasmid miniprep kit was purchased from OMEGA company; his tag protein purification kit, goat anti-rabbit IgG (H+L) HRP antibody was purchased from Kangshen Biotechnology Co., ltd; pre-stained protein markers were purchased from GenStar.
Step 3: primer design and Synthesis
The Hcp gene specific primer is designed according to the sequence of the Hcp gene, and restriction enzyme cutting sites are EcoR I and Xho I respectively. Hcp-F:5'- -3': CCGGAATTCATGCCAACTCCATGTTATAT; hcp-R:5'- -3': CGGCTCGAGTTACGCCTCGATCGGAGCAC A
Step 4: amplification of Hcp Gene
PCR amplification is carried out by taking DNA of AH-SC-3 as a template and Hcp-F/R as a primer pair, and the PCR product is subjected to gel recovery according to the operation instruction of a gel recovery kit.
Step 5: construction of prokaryotic expression plasmid pET-32a-Hcp
And (3) carrying out double enzyme digestion on a glue recovery product of the target gene Hcp and the pET-32a (+) vector, then carrying out glue recovery again, connecting the two fragments according to a T4 ligase specification, and converting the connection product into DH5 alpha competent cells according to a DH5 alpha competent cell using specification. The plasmid was extracted according to the instructions of the plasmid extraction kit after single colony propagation on the next day. The obtained plasmid was subjected to enzyme digestion, identified and sequenced, and designated pET-32a-Hcp.
Step 6: inducible expression of recombinant Hcp protein and optimization of expression conditions
PET-32a-Hcp was transformed into BL21 competent cells according to the instructions and plated on ampicillin-resistant LA plates and incubated in a incubator at 37℃for 12h. Single colony culture is selected and cultured for 6 hours at 37 ℃ and at 150rpm, partial bacterial liquid is taken for PCR identification, and positive clones with correct identification are subjected to enrichment culture. Optimal induction conditions were determined by adding different doses of IPTG after the logarithmic growth phase was reached and varying the induction time. The supernatant was collected at 8,000 rpm for 3min, the pellet was resuspended in 40. Mu.L of PBS and mixed with 10. Mu.L of 5X Loading Buffer, and after 10min in boiling water, SDS-PAGE was performed.
Step 7: identification and purification of recombinant Hcp protein expression forms
Performing ultrasonic lysis on the expressed bacterial liquid, separating supernatant and precipitate from the lysate at 4 000rpm for 10min, and dissolving the precipitate in Inclusion Body Elutio Buffer. 40. Mu.L of the supernatant and the pellet solution were mixed with 10. Mu.L of 5X Loading Buffer, and subjected to SDS-PAGE after 10min in boiling water. A number of inductions were performed after the expression pattern was determined. The protein was purified according to the method in the purification kit.
Amplification of the Hcp gene and construction of a prokaryotic expression vector, and gel electrophoresis results show that the amplification result is obtained to obtain a 519bp target fragment (see figure 1A). The result of gel electrophoresis showed that the pET-32a-Hcp double cleavage gave a fragment of about 519bp in size and a fragment of 5.9kbp, which was consistent with the expectations (see FIG. 1B). The homology of the sequencing result with the reference sequence is 100%. See fig. 1A: hcp gene amplification results. M: DNA molecular weight standard (DL 2 000); 1: hcp gene PCR amplification products; see fig. 1B; double enzyme digestion identification of pET-32a-Hcp recombinant plasmid; m: DNA molecular weight standard (DL 10 000); 1: the pET-32a-Hcp recombinant plasmid enzyme cutting product.
The conditions for Hcp expression of the recombinant protein were optimized, and the result showed that the expressed target protein was about 37ku, which is consistent with the expected size (see fig. 2A, B). The protein expression level was increased when the induction final concentration was increased (see FIG. 2A), whereas the protein expression level was not significantly increased when the induction time was increased (see FIG. 2B). Fig. 2A: fumbling results for optimal IPTG induction concentration of pET-32a-Hcp protein: protein molecular mass standard.1: pET-32a (+) empty vector; 2: pET-32a-Hcp was not induced; 3-7: the final concentration of IPTG was 0.2mmol/L, 0.4mmol/L, 0.6mmol/L, 0.8mmol/L and 1.0mmol/L, respectively, of the induced recombinant AH Hcp protein. Fig. 2B: fumbling results for the optimal induction time of pET-32a-Hcp protein: protein molecular mass standard.1: pET-32a (+) empty vector; 2: pET-32a-Hcp was not induced; 3-7: the induction time is respectively 2h, 4h, 6h, 8h and 10h of induced recombinant AH Hcp protein.
Identification and purification of the expression form of the recombinant protein Hcp, and SDS gel electrophoresis results show that the recombinant protein Hcp exists in the supernatant and the sediment (see figure 3), and the expression amount in the supernatant is higher as shown in the figure. The size of the purified protein was consistent with the expected. In fig. 3, M: protein molecular mass standard; 1: pET-32a (+) empty vector; 2: pET-32a-Hcp induction; 3: pET-32a-Hcp was not induced; 4: inducing the supernatant after crushing by pET-32 a-Hcp; 5: pET-32a-Hcp is induced to be crushed and then deposited; 6: purifying the expression of pET-32 a-Hcp.
The Hcp protein has basic physicochemical properties, the Hcp protein consists of 172 amino acids, and the most amino acids are valine (Val) and threonine (Thr), which account for 8.7 percent. The molecular formula of the protein is C 846H1304N224O259S8, the relative molecular mass is 19013.49, and the theoretical isoelectric point is 5.24. The total number of positive charge residues carried by the protein is 138, and the total number of negative charge residues is 20. The total average hydrophilicity (GRAVY) of the protein is-0.273, which belongs to hydrophilic protein, the hydrophobicity of amino acid No. 117 is strongest, the value is 1.433, and the hydrophilicity of amino acid No. 55 is strongest, the value is-1.911. The protein fat coefficient was 73.66, the instability coefficient was 32.03, and the protein was stable. The Hcp protein was analyzed for hydrophilicity and hydrophobicity using ProtScale, with amino acid scores less than 0 indicating hydrophilicity and scores greater than 0 indicating hydrophobicity. Analysis showed that most of the amino acids of Hcp protein were located in the hydrophilic region, which was hydrophilic protein, consistent with the results of physicochemical analysis of the protein, as shown in fig. 4.
Signal peptide and transmembrane domain predictions of Hcp protein, signalP5.0 analysis (FIGS. 5-6) showed that Hcp protein has no signal cleavage site, and that Hcp protein is presumed to contain no signal peptide, belonging to a non-secreted protein. The TMHMM2.0 prediction (FIG. 8) shows that the probability of the protein in the transmembrane region (transmembrane) and the intramembrane region (inside) is very low, and the probability in the extracellular region (outside) is close to 1, indicating that the Hcp protein has no transmembrane domain and is located entirely in the extracellular region.
Phosphorylation site and conserved domain of Hcp protein the phosphorylation site of Hcp protein was predicted using netphos3.1, and when the threshold was 0.5, the protein was predicted to have a total of 30 phosphorylation sites (fig. 7), including 11 serine (Serine), 15 threonine (Threonine) and 4 Tyrosine (Tyrosine). The Hcp protein was predicted to contain a conserved domain (fig. 8), belonging to the Hcp1 family of T6SS secretion systems, the outer membrane channel protein family, using NCBI's CD-search tool. As shown in fig. 9, the third red on the left is serine phosphorylation site; the first red on the left is threonine phosphorylation site; the second blue on the left is the tyrosine phosphorylation site; the purple line is a broad value.
The secondary and tertiary structures of Hcp proteins were predicted using SPOMA software and consisted of mainly Random coil (Random coil), extended strand (Extended strand), 25.00%, alpha-helix (Alpha helix), 19.19%, beta-turn (Beta turn), 4.07% (fig. 9). By using the three-level structure MODEL (fig. 10) of SWISS-MODEL prediction, the global MODEL quality estimation (global MODEL quality estimation, GMQE) value obtained by prediction is 0.95, and the gmqe value can simply evaluate the quality of the prediction MODEL, and the closer the value is to 1, the better the modeling quality is, and the reliable the prediction result is.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (6)
1. The preparation method of the recombinant aeromonas hydrophila Hcp protein is characterized by comprising the following steps: the method comprises the following steps:
step 1: designing and synthesizing a primer;
step 2: amplifying the Hcp gene;
Step 3: construction of prokaryotic expression plasmid pET-32 a-Hcp;
step 4: performing induction expression and expression condition optimization of recombinant Hcp protein;
step 5: identification and purification of the expression form of the recombinant Hcp protein.
2. The method for producing a recombinant aeromonas hydrophila Hcp protein according to claim 1, wherein: the specific process of the step 1 is as follows:
designing an Hcp gene specific primer according to the sequence of the Hcp gene, wherein restriction enzyme cutting sites are EcoR I and Xho I respectively;
Hcp-F:5'--3':CCGGAATTCATGCCAACTCCATGTTATAT;
Hcp-R:5'--3':CGGCTCGAGTTACGCCTCGATCGGAGCAC。
3. the method for producing a recombinant aeromonas hydrophila Hcp protein according to claim 1, wherein: the specific process of the step 2 is as follows:
PCR amplification is carried out by taking DNA of AH-SC-3 as a template and Hcp-F/R as a primer pair, and the PCR product is subjected to gel recovery according to the operation instruction of a gel recovery kit.
4. The method for producing a recombinant aeromonas hydrophila Hcp protein according to claim 1, wherein: the specific process of the step 3 is as follows:
And (3) carrying out double enzyme digestion on a glue recovery product of the target gene Hcp and a pET-32a (+) vector, then carrying out glue recovery again, connecting the two fragments according to a T4 ligase specification, converting the connecting product into DH5 alpha competent cells according to a DH5 alpha competent cell using specification, extracting plasmids according to a plasmid extraction kit operating specification after single colony propagation in the next day, carrying out enzyme digestion identification and sequencing on the obtained plasmids, and naming the plasmids as pET-32a-Hcp.
5. The method for producing a recombinant aeromonas hydrophila Hcp protein according to claim 1, wherein: the specific process of the step 4 is as follows:
pET-32a-Hcp is transformed into BL21 competent cells according to the specification, the BL21 competent cells are coated on an ampicillin-resistant LA plate, the LA plate is cultured for 12 hours in a constant temperature incubator at 37 ℃, single colony is selected for culturing at 37 ℃ and at 150rpm, part of bacterial liquid is taken for PCR identification, positive clones which are identified correctly are subjected to enrichment culture, optimal induction conditions are determined by adding different doses of IPTG and changing induction time after the logarithmic growth phase is reached, supernatant is discarded after 8-000 rpm 3min of bacterial liquid is collected, 40 mu L of PBS is added for resuspension precipitation and mixing with 10 mu L of 5X Loading Buffer, and SDS-PAGE electrophoresis is carried out after 10min of boiling water bath.
6. The method for producing a recombinant aeromonas hydrophila Hcp protein according to claim 1, wherein: the specific process of the step 5 is as follows:
performing ultrasonic lysis on the expressed bacterial liquid, separating supernatant and precipitate at 4 000rpm for 10min, dissolving the precipitate in Inclusion Body Elutio Buffer, mixing 40 mu L of supernatant and precipitate solution with 10 mu L of 5× Loading Buffer, performing SDS-PAGE electrophoresis after 10min in boiling water, determining expression form, inducing, and purifying protein according to the method in the purification kit.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410113384.1A CN118027160A (en) | 2024-01-26 | 2024-01-26 | Preparation method of recombinant Aeromonas hydrophila Hcp protein |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202410113384.1A CN118027160A (en) | 2024-01-26 | 2024-01-26 | Preparation method of recombinant Aeromonas hydrophila Hcp protein |
Publications (1)
Publication Number | Publication Date |
---|---|
CN118027160A true CN118027160A (en) | 2024-05-14 |
Family
ID=90996261
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202410113384.1A Pending CN118027160A (en) | 2024-01-26 | 2024-01-26 | Preparation method of recombinant Aeromonas hydrophila Hcp protein |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN118027160A (en) |
-
2024
- 2024-01-26 CN CN202410113384.1A patent/CN118027160A/en active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN110551732A (en) | Trachinotus ovatus antimicrobial peptide LEAP-2 gene and application thereof | |
CN106866825B (en) | Silkworm internal reference protein GAPDH polyclonal antibody and preparation method thereof | |
CN112851792B (en) | Preparation method and application of grass carp TNF-alpha recombinant protein | |
CN102180961B (en) | Black-blue spotted puffer fish interferon IFN gamma 2 and preparation method and application thereof | |
CN108101974B (en) | Fasciola hepatica multi-epitope fusion diagnostic antigen and application and preparation method thereof | |
CN109997970B (en) | Acidic xylanase mutant with improved enzyme activity and heat resistance, and coding gene and application thereof | |
CN118027160A (en) | Preparation method of recombinant Aeromonas hydrophila Hcp protein | |
CN115873733B (en) | Pichia pastoris strain for high yield of lysozyme and application thereof | |
CN108484766B (en) | Anti-toxoplasma Thioredoxin nano antibody and coding gene and application thereof | |
CN107602686B (en) | Polypeptide with resistance to gram-positive bacteria | |
CN114437237B (en) | Staphylococcus aureus TRAP targeting recombinant protein antigen and application thereof | |
CN102199202B (en) | Gene of recombinant fungal immunomodulatory protein between ganodermas, protein coded thereby, and application thereof | |
CN118027186A (en) | Preparation method of aeromonas hydrophila Hcp protein polyclonal antibody | |
CN110819645B (en) | Fancy carp Gtpch2 gene, coded protein and application thereof | |
CN104480126A (en) | Trachinotus ovatus peroxiredoxin gene | |
CN104818283B (en) | The gene of porcine interferon alpha 8 and its expression of a kind of optimization | |
CN111019952B (en) | Antifungal gene, polypeptide, recombinant protein, preparation method and application thereof | |
CN111925433A (en) | Outizua erythropolis IFN alpha protein clone expression and polyclonal antibody preparation | |
CN102586257A (en) | Sika deer IGF (Insulin-like Growth Factor)-1 polypeptide and preparation method thereof | |
CN108048475B (en) | Sinonovacula constricta I type lysozyme-2 gene, encoding protein and construction method of recombinant sinonovacula constricta I type lysozyme-2 gene engineering bacteria | |
CN102180962A (en) | Tetraodon nigroviridis interferon IFNgamma1 and preparation method and application thereof | |
CN110055259A (en) | Grass carp Akirin2 gene, coding albumen and its application | |
CN118421638A (en) | FADD protein and preparation method thereof | |
CN112043836B (en) | Seawater medaka HSP90ab1 gene and application of encoding protein thereof | |
CN118165124B (en) | Fusion protein of recombinant porcine interferon lambda 1, porcine interferon gamma and porcine Fc and application thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |